DJO | Digital Journal of Ophthalmology

Welcome, please sign in


A 39-year-old woman with unilateral metamorphosias Digital Journal of Ophthalmology 2011 Volume 17, Number 4 November 20, 2011 DOI: 10.5693/djo.03.2011.11.001	Printer Friendly Download PDF

Lígia Ribeiro \| Department of Ophthalmology, Centro Hospitalar Vila Nova de Gaia, Portugal Sidnei Barge \| Department of Ophthalmology, Centro Hospitalar Vila Nova de Gaia, Portugal Luís Silva \| Department of Ophthalmology, Centro Hospitalar Vila Nova de Gaia, Portugal Arnaldo Brandão \| Department of Ophthalmology, Centro Hospitalar Vila Nova de Gaia, Portugal Dália Meira \| Department of Ophthalmology, Centro Hospitalar Vila Nova de Gaia, Portugal
HISTORY EXAMINATION ANCILLARY TESTING TREATMENT DIFF. DIAGNOSIS DIAGNOSIS AND DISCUSSION REFERENCES
Treatment
The patient was treated with two monthly intravitreal injections of 0.05 mL/0.5 mg ranibizumab, without ocular or systemic complications. Four months after presentation, her visual acuity had improved to 1.0 and the metamorphopsias had resolved. Fluorescein angiography showed resolution of the choroidal neovascular lesion and complete resolution of the hemorrhage (Figure 2). Fluorescein angiography at 18 months' follow-up showed no recurrence of the choroidal neovascular membrane and her vision remained stable. No systemic or ocular adverse events were noted.
top
Figure 2 Fundus photographs and fluorescein angiograms of left eye before and 1, 4, and 18 months after intravitreal ranibizumab injections showing resolution of the hemorrhage and the choroidal neovascular membrane. The pretreatment fundus photograph shows a juxtafoveal choroidal neovascular membrane with multiple small chorioretinal lesions. Early and late phases of fluorescein angiogram showed window defects with no evidence of leakage.